![A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam - ScienceDirect A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0302283812008342-gr2.jpg)
A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam - ScienceDirect
![SciELO - Brasil - Prostatic specific antigen for prostate cancer detection Prostatic specific antigen for prostate cancer detection SciELO - Brasil - Prostatic specific antigen for prostate cancer detection Prostatic specific antigen for prostate cancer detection](https://minio.scielo.br/documentstore/1677-6119/rZqzS6ngfHjyJxNWvHmW5qy/3aad0880313aaaa98232afa144d67ec911e27a25.gif)
SciELO - Brasil - Prostatic specific antigen for prostate cancer detection Prostatic specific antigen for prostate cancer detection
![Free to total serum prostate specific antigen ratio in symptomatic men does not help in differentiating benign from malignant disease of the prostate Free to total serum prostate specific antigen ratio in symptomatic men does not help in differentiating benign from malignant disease of the prostate](https://indianjurol.com/articles/2014/30/1/images/IndianJUrol_2014_30_1_28_124202_t3.jpg)
Free to total serum prostate specific antigen ratio in symptomatic men does not help in differentiating benign from malignant disease of the prostate
![Correlation between the complex PSA/total PSA ratio and the free PSA/total PSA ratio, sensitivity and specificity of both markers for the diagnosis of prostate cancer. | Semantic Scholar Correlation between the complex PSA/total PSA ratio and the free PSA/total PSA ratio, sensitivity and specificity of both markers for the diagnosis of prostate cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ac4ab721c7e17a9b1cb04ea629b66a283e875bd1/3-Table1-1.png)
Correlation between the complex PSA/total PSA ratio and the free PSA/total PSA ratio, sensitivity and specificity of both markers for the diagnosis of prostate cancer. | Semantic Scholar
![Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0) | BMJ Open Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0) | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/12/4/e053118/F1.large.jpg)
Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0) | BMJ Open
![PSA Screening — Dr James Thompson is an experienced Urological Surgeon specialising in robotic surgery for prostate and bladder cancer PSA Screening — Dr James Thompson is an experienced Urological Surgeon specialising in robotic surgery for prostate and bladder cancer](https://images.squarespace-cdn.com/content/v1/5d09944f1c172000010bf8dd/1568690705667-CW3OJFH7SSPHFS7JYCGK/Untitled-5-01.png)
PSA Screening — Dr James Thompson is an experienced Urological Surgeon specialising in robotic surgery for prostate and bladder cancer
![Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening | Scientific Reports Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-77668-w/MediaObjects/41598_2020_77668_Fig1_HTML.png)
Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening | Scientific Reports
![Prostate‐specific antigen: Current status - Brawer - 1999 - CA: A Cancer Journal for Clinicians - Wiley Online Library Prostate‐specific antigen: Current status - Brawer - 1999 - CA: A Cancer Journal for Clinicians - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/6c7e7530-c8b6-4df6-8283-ff36519db3a2/mtbl010.jpg)
Prostate‐specific antigen: Current status - Brawer - 1999 - CA: A Cancer Journal for Clinicians - Wiley Online Library
![A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor | Scientific Reports A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-43427-9/MediaObjects/41598_2019_43427_Fig1_HTML.png)
A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor | Scientific Reports
![SciELO - Brasil - Prostatic specific antigen for prostate cancer detection Prostatic specific antigen for prostate cancer detection SciELO - Brasil - Prostatic specific antigen for prostate cancer detection Prostatic specific antigen for prostate cancer detection](https://minio.scielo.br/documentstore/1677-6119/rZqzS6ngfHjyJxNWvHmW5qy/4966e23dbbb57e0e806f4c569f2439f76166ebb8.gif)
SciELO - Brasil - Prostatic specific antigen for prostate cancer detection Prostatic specific antigen for prostate cancer detection
![MP56-09 A RISK CALCULATOR INCORPORATING MRI-GUIDED BIOPSY DATA TO PREDICT CLINICALLY SIGNIFICANT PROSTATE CANCER | Journal of Urology MP56-09 A RISK CALCULATOR INCORPORATING MRI-GUIDED BIOPSY DATA TO PREDICT CLINICALLY SIGNIFICANT PROSTATE CANCER | Journal of Urology](https://www.auajournals.org/cms/asset/c14cc58a-dba4-426f-9e72-f09b0e565ced/ju.0000000000000925.09t1.gif)
MP56-09 A RISK CALCULATOR INCORPORATING MRI-GUIDED BIOPSY DATA TO PREDICT CLINICALLY SIGNIFICANT PROSTATE CANCER | Journal of Urology
![The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging](https://ars.els-cdn.com/content/image/1-s2.0-S2666168322005924-gr1.jpg)
The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging
![SciELO - Brasil - Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and SciELO - Brasil - Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and](https://minio.scielo.br/documentstore/1677-6119/5GWVS9m8y55TZvZ89YVmVbz/e3f287786901ff1f9230b1df00909c7c5795c03c.gif)